Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PANZYGA in pediatric chronic immune thrombocytopenia
2019-004063-49Phase 4
- Sponsor
- Octapharma
- Start
- Oct 2019
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of polyvalent human immunoglobulin in immune thrombocytopenia (ITP), sponsored by Octapharma. Primary endpoint: Response rate by Day 8.
02
Drugs
polyvalent human immunoglobulin
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on 2019-004063-49.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-004063-49.